25
Sep
Canagliflozin And Cardiovascular And Renal Events. Canagliflozin and Cardiovascular and Renal Events In Type 2 Diabetes Oct 21 2017 Canagliflozin may reduce the risk of major cardiovascular complication but amputation risk is increased. In the trials of the Canagliflozin Cardiovascular Assessment Study CANVAS Program Aug. In the CANVAS clinical trial canagliflozin reduced the risk of adverse major cardiovascular events CV death non-fatal myocardial infarction and stroke hospitalization for heart failure and. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure body weight and albuminuria in people with diabetes. Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure body weight and albuminuria in people with diabetes. 2020 Feb 4141 5407-410. The canagliflozin group also had a lower risk of cardiovascular death myocardial infarction or stroke hazard ratio 080. Patients with type 2 diabetes and established cardiovascular disease or at high risk for cardiovascular events who were treated with canagliflozin had significantly lower rates of the primary. 95 CI 067 to 095.
2020 Feb 4141 5407-410.
We report the effects of treatment with canagliflozin on cardiovascular renal and safety outcomes. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. The report combines the data from two trials CANVAS and CANVAS-Renal which were designed to evaluate the safety and effect of canagliflozin an SGLT-2 inhibitor on the appearance of cardiovascular and renal events in patients with type 2 diabetes. Patients with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular outcomes compared with the primary prevention patients. We found that canagliflozin reduced the risk of both cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease without a significant interaction across the spectrum of baseline HbA1c values which included patients with baseline HbA1c between 65 and 7 suggesting that treatment of patients with chronic kidney disease or atherosclerotic cardiovascular disease is warranted even if their diabetes mellitus is well controlled.